Literature DB >> 23251747

Recommending aspirin for primary prevention in diabetic patients: what may we conclude from the data?

Antonio Nicolucci.   

Abstract

Entities:  

Year:  2011        PMID： 23251747      PMCID： PMC3513879          DOI： 10.1177/2040622311400116

Source DB:  PubMed          Journal:  Ther Adv Chronic Dis        ISSN： 2040-6223            Impact factor:   5.091


× No keyword cloud information.
  20 in total

Review 1.  Management of cardiovascular disease in patients with diabetes: the 2008 Canadian Diabetes Association guidelines.

Authors:  Onil K Bhattacharyya; Baiju R Shah; Gillian L Booth
Journal:  CMAJ       Date:  2008-09-18       Impact factor: 8.262

Review 2.  Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials.

Authors:  Kenneth R McQuaid; Loren Laine
Journal:  Am J Med       Date:  2006-08       Impact factor: 4.965

3.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.

Authors: 
Journal:  BMJ       Date:  2002-01-12

Review 4.  Prevention of cardiovascular disease in type-2 diabetes: how to improve the clinical efficacy of aspirin.

Authors:  Virgilio Evangelista; Licia Totani; Serenella Rotondo; Roberto Lorenzet; Gianni Tognoni; Giorgia De Berardis; Antonio Nicolucci
Journal:  Thromb Haemost       Date:  2005-01       Impact factor: 5.249

5.  Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections.

Authors:  H King; R E Aubert; W H Herman
Journal:  Diabetes Care       Date:  1998-09       Impact factor: 19.112

6.  A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.

Authors:  Paul M Ridker; Nancy R Cook; I-Min Lee; David Gordon; J Michael Gaziano; Joann E Manson; Charles H Hennekens; Julie E Buring
Journal:  N Engl J Med       Date:  2005-03-07       Impact factor: 91.245

7.  Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial.

Authors:  Michele Sacco; Fabio Pellegrini; Maria C Roncaglioni; Fausto Avanzini; Gianni Tognoni; Antonio Nicolucci
Journal:  Diabetes Care       Date:  2003-12       Impact factor: 19.112

8.  Similarity of the impact of type 1 and type 2 diabetes on cardiovascular mortality in middle-aged subjects.

Authors:  Auni Juutilainen; Seppo Lehto; Tapani Rönnemaa; Kalevi Pyörälä; Markku Laakso
Journal:  Diabetes Care       Date:  2007-12-14       Impact factor: 19.112

9.  Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications.

Authors:  Sonia Hernández-Díaz; Luis A García Rodríguez
Journal:  BMC Med       Date:  2006-09-20       Impact factor: 8.775

10.  The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease.

Authors:  Jill Belch; Angus MacCuish; Iain Campbell; Stuart Cobbe; Roy Taylor; Robin Prescott; Robert Lee; Jean Bancroft; Shirley MacEwan; James Shepherd; Peter Macfarlane; Andrew Morris; Roland Jung; Christopher Kelly; Alan Connacher; Norman Peden; Andrew Jamieson; David Matthews; Graeme Leese; John McKnight; Iain O'Brien; Colin Semple; John Petrie; Derek Gordon; Stuart Pringle; Ron MacWalter
Journal:  BMJ       Date:  2008-10-16
View more
  1 in total

1.  HUCMNCs protect vascular endothelium and prevent ISR after endovascular interventional therapy for vascular diseases in T2DM rabbits.

Authors:  Haixia Ding; Tong Zhang; Yaping Du; Bei Liu; Yueqin Liu; Fujun Wang
Journal:  Mol Cell Biochem       Date:  2017-05-04       Impact factor: 3.396
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.